According to the results of the Connectivity map (CMap) database (Supplementary Figure 8), the HDAC inhibitor [74] may be a promising drug that can antagonize the ND-T2D process (Supplementary Table 5), and the spleen tyrosine kinase (SYK) inhibitor, fostamatinib [75], can reverse the progression of IGT-T2D (Supplementary Table 6). This evidence concerns the gene SYK and type 2 diabetes mellitus.